Loading clinical trials...

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM: A Randomized, Bouble-Blind, Placebo-Controlled Phase Ib Trial

NCT07020949•Tonghua Dongbao Pharmaceutical Co.,Ltd

View on ClinicalTrials.gov

Summary

The aim of this trial is to investigate the safety, tolerability, pharmacokinetics, and efficacy of THDBH120 injection in participants with T2DM. This study includes three multiple-ascending dose cohorts.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Male or female patients 18 to 75 years of age, inclusive;
•Have T2DM for at least 6 months before screening based on the disease diagnostic criteria (World Health Organization \[WHO\] Classification for Diabetes);
•Treated with diet and exercise alone, or a stable dose of metformin (≥1000 mg/day and not more than the locally approved dose) for at least 2 months prior to screening;
•Have a BMI between 23 and 35 kg/m²(inclusive) at screening;
•HbA1c levels: 7.0% to 10.0% (inclusive) for subjects treated by diet or exercise alone; 7.0% to 9.0% (inclusive) for subjects receiving stable-dose metformin.

Exclusion Criteria

•Have been diagnosed with proliferative diabetic retinopathy, diabetic maculopathy, or non-proliferative diabetic retinopathy requiring treatment during the study;
•Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia type 2;
•Have diagnosed hyperthyroidism or hypothyroidism;
•Have grade 2 hypoglycemia events or grade 3 hypoglycemia events within 6 months prior to screening;
•Have a history of ketoacidosis, lactic acidosis, or hyperosmolar state leading to hospitalization within 6 months prior to screening;
•Presence of uncontrolled hypertension at screening: systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg;
•Prolonged QTcF interval on 12-lead ECG at screening (QTcF≥450 ms for males, \>470 ms for females), PR interval \>200 ms, or the presence of long QT syndrome, second- or third-degree atrioventricular block, left or right bundle branch block, Wolff-Parkinson-White syndrome, or any other clinically significant arrhythmias (except sinus arrhythmia);
•Weight change ≥ 5% within 3 months prior to screening;
•Have been treated with insulin, excluding insulin therapy for gestational diabetes mellitus, or acute/temporary insulin therapy (≤ 14 days) for conditions such as acute illness, hospitalization, or elective surgery.

Locations (1)

Peking University First Hospital

Beijing, China

Key Dates

Start Date

June 13, 2024

Primary Completion Date

November 27, 2024

Completion Date

November 27, 2024

Last Updated

June 13, 2025

Enrollment

ACTUAL participants

Conditions

Diabetes Mellitus Type 2

Interventions

THDBH120 injection

DRUG

Placebo of THDBH120 injection

DRUG

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

NCT06525259

Diabetes Mellitus Type 2, Childhood-Onset

View study

RECRUITINGNA

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

NCT07011147

Type 1 Diabetes (T1D)Type 2 Diabetes+9 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM

Inclusion Criteria

Exclusion Criteria

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

Impact of Long Alimentary Limb or Long Biliary Limb Roux-en-Y Gastric Bypass on Type 2 Diabetes Remission in Severely Obese Patients.

Therapeutic Efficacy and Safety Evaluation of AI in the Management of Diabetes: A RCT Trial

The Effect of Propolis Administration on Cholesterol Level in Diabetic Type 2 Patients

App-based Diabetes Management and Community-based Interventions